5-Amino-1MQ

5-Amino-1MQ (full chemical name: 5-amino-1-methylquinolinium) is a synthetic small molecule, not a peptide in the classical sense — it lacks an amino acid chain structure — but is frequently categorized alongside research peptides due to overlapping vendor ecosystems and biohacker interest profiles. It is a cell-permeable, selective inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that catalyzes the methylation of nicotinamide using S-adenosylmethionine (SAM) as a methyl donor. NNMT is expressed at high levels in adipose tissue and has been associated with metabolic dysfunction, obesity, and cellular aging in preclinical research.

The proposed mechanism centers on NNMT's role as a regulator of the methionine cycle and NAD+ precursor availability. By inhibiting NNMT, 5-Amino-1MQ is theorized to shift the balance toward higher intracellular NAD+ levels and reduce the availability of SAM for pro-adipogenic epigenetic modifications. Animal studies — including work published in Nature Communications (Neelakantan et al., 2019) using diet-induced obese mouse models — reported reductions in fat mass, body weight, and adipocyte size in treated animals compared to controls, without apparent changes in food intake. The same research group observed increases in energy expenditure markers, suggesting a thermogenic or mitochondrial component to the compound's action. These findings remain in murine models; direct extrapolation to human physiology requires significant caution.

Evidence Summary: The strongest published data come from animal studies (primarily rodent), with the Neelakantan 2019 Nature Communications paper representing the most-cited mechanistic anchor. That study used in vitro cell cultures and diet-induced obese mice, reporting statistically significant reductions in adipocyte differentiation and fat mass. No peer-reviewed, controlled human clinical trials have been published as of this writing. User self-reports circulating in biohacker communities (forums such as Longecity and various Reddit communities) describe anecdotal observations consistent with body recomposition, appetite modulation, and increased energy — but these are uncontrolled, unblinded, and not systematically collected. They should be weighted accordingly: as hypothesis-generating signals only, not evidence of efficacy.

Dosing in Research Contexts: Animal studies have employed a range of dosing protocols; the Neelakantan group used doses scaled to murine body weight that do not translate directly to human equivalents via simple conversion. Some research-community discussions reference oral doses in the range of 50–150 mg per day in human self-experimentation contexts, but this range is derived from extrapolation and anecdote rather than clinical pharmacokinetic data. This information is reported for educational purposes only and does not constitute a dosing recommendation. No established safe or effective dose has been determined for human use. Anyone citing specific human dose protocols is doing so without a clinical evidence base.

Legal Status and Sourcing: 5-Amino-1MQ is not approved for human therapeutic use by the FDA, MHRA, EMA, or TGA. It occupies a research-chemical status in most jurisdictions, meaning it is legal to purchase for in vitro or laboratory research purposes but not intended, labeled, or approved for human consumption. Sourcing considerations should prioritize vendors who provide third-party HPLC and mass spectrometry certificates of analysis (COA) confirming identity and purity, disclose synthesis source, and require age verification. The compound should be stored according to vendor specifications — typically in a cool, dry, dark environment — and handled with appropriate laboratory precautions. This profile is for educational purposes only and does not constitute medical or clinical advice.